Immunization

A new 25-valent pediatric pneumococcal vaccine enters phase 3 after strong data, aiming for broader coverage and improved serotype 3 protection.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.

Researchers explore invasive pneumococcal disease epidemiology after the introduction of multiple pneumococcal conjugate vaccines.

Amid shifting vaccine recommendations and an evolving health care landscape, pharmacists continue to weather the storm as frontline community immunizers.

In adult patients at least 50 years old, researchers estimated lifetime costs and health outcomes of the 23-valent pneumococcal polysaccharide vaccine.

In part 2 of our World Immunization Week interview with Nathan Ott, PharmD, he discusses the power of collaboration and continuing education in boosting vaccine awareness.

A head-to-head trial shows a protein-based COVID-19 booster causes fewer adverse effects, boosting patient preference and aiding pharmacists.

Low pneumococcal vaccine rates have potential to significantly impact a variety of at-risk populations, even groups of certain health care workers.

New research shows older adults vaccinate more when confident navigating their health care.

Exploring both patient-level and organizational factors, researchers assess community pharmacy accessibility for immunizations and injectables.

Meta-analysis shows PCV13 followed by PPSV23 boosts pneumococcal immunity in seniors without added adverse effects.

Social determinants of health shape pneumococcal risk, making vaccination especially important for specific populations.

Pharmacists expand vaccine access, but billing rules, payer barriers, and uneven reimbursement keep immunization services from scaling nationwide.

Investigators of the multicenter cohort aim to determine if the 13-valent pneumococcal conjugate vaccine impacted disease activity over a 24-month period.

Ashley Chinchilla, PharmD, BCACP, presents on the persistence of vaccine hesitancy among patients and the powerful tools used to address it.

As population-level introduction of pneumococcal conjugate vaccines has led to an increase in invasive disease, the development of higher-valency vaccines has become a primary solution.

Serotype 19F resurges despite PCVs, raising invasive disease risk in older adults; pharmacists track immune evasion, variants, and boost adherence.

Gretchen Garofoli, PharmD, BCACP, CTTS, FAPhA, provides her perspective on the back-and-forth stemming from the federal government regarding US vaccine guidelines.

Phase 3 data show a 6-valent Lyme vaccine cuts confirmed cases by 73%, paving the way for 2026 filings and new prevention options.

Along with presenting best practices for pharmacies’ vaccination workflows, researchers explore the impact of community pharmacies offering technician-administered vaccines.

With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden.

MAHA-driven HHS shifts vaccines and nutrition, fueling public health debate as pharmacists battle social media misinformation and rebuild trust.

CDC researchers investigate pneumococcal disease cases and intervention strategies within a North Carolina correctional facility from June 14 to July 30, 2024.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Researchers investigate PCV25 developments and potential use of the vaccine among adults who are healthy and naïve to the pneumococcal vaccine.